Role of CRH in the pathogenesis of dementia of Alzheimer's type and other dementias

Current Opinion in Investigational Drugs

Volumn 3, Issue 11, 2002, Pages 1637-1642

  Rehman, Habib U ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

Alzheimer's disease; Corticotrophin releasing hormone; Dementia

Indexed keywords

ADENYLATE CYCLASE; ARGIPRESSIN; CATECHOLAMINE DERIVATIVE; CHOLINE ACETYLTRANSFERASE; CORTICOSTEROID; CORTICOSTEROID RECEPTOR; CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR HORMONE RECEPTOR BLOCKING AGENT; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; DEXAMETHASONE; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HORMONE; HORMONE RECEPTOR BLOCKING AGENT; HYDROCORTISONE; LONG ACTING DRUG; MINERALOCORTICOID RECEPTOR; NEUROTRANSMITTER; OXYTOCIN; PEPTIDE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; ALZHEIMER DISEASE; BRAIN; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; HORMONAL REGULATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; HUNTINGTON CHOREA; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOREACTIVITY; NEGATIVE FEEDBACK; NERVE CELL EXCITABILITY; NEUROANATOMY; NEUROSECRETORY CELL; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PROGRESSIVE SUPRANUCLEAR PALSY; RECEPTOR BINDING; REVIEW;

ALZHEIMER DISEASE; ANIMALS; CORTICOTROPIN-RELEASING HORMONE; DEMENTIA; HUMANS;

EID: 0036881432     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Katzmann R: Alzheimer's disease. N Engl J Med (1986) 314:964-973.
2. Perry EK, Gibson PH, Blessed G et al: Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. J Neurological Sci (1981) 49:419-428.
3. Coyle JT, Price DL, DeLong MR: Alzheimer's disease: A disorder of cortical cholinergic innervation. Science (1983) 219:1184-1190.
4. Davies P, Wolozin BL: Recent advances in teh neurochemistry of Alzheimer's disease. J Clin Psychiatry (1987) 48:23-30.
5. Maragos WF, Greenamyre JT, Penney JB, Young AB: Glutamate dysfunction in Alzheimer's disease: An hypothesis. Trends Neurosci (1987) 10:65-68.
6. Whitehouse PJ: Neurotransmitter receptor alterations in Alzheimer's disease: A review. Alzheimer Dis Assoc Disord (1987) 1:9-18.
7. Arbiser JL, Morton CC, Bruns GA, Majzoub JA: Human corticotrophin-releasing hormone gene is located on the long arm of chromosome 8. Cytogenet Cell Genet (1998) 47:113-116.
8. Owens MJ, Nemeroff CB: Physiology and pharmacology of corticotrophin-releasing factor. Pharmacol Rev (1991) 43:425-473.
9. Whitnall MH, Smyth D, Gainer H: Vasopressin coexists in half of the corticotrophin-releasing factor axons present in the external zone of the median eminence in normal rats. Neuroendocrinology (1987) 45:420-424.
10. Whitnall MH: Stress selectively activates the vasopressin-containing subset of corticotrophin-releasing hormone neurons. Neuroendocrinology (1989) 50:702-707.
11. Swanson LW, Sawchenko OE, Rivier J, Vale WW: Organization of ovine corticotrophin-releasing factor immunoreactive cells and fibres in the rat brain: An immunohistochemical study. Neuroendocrinology (1983) 36:165-186.
12. Holsboer F, Spengler D, Heuser I: The role of corticotrophin-releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res (1992) 93:385-417.
13. De Kloet ER, Vreugdenhil E, Oitzl MS, Joels M: Brain corticosteroid receptor balance in health and disease. Endocr Rev (1998) 19:269-301.
14. De Souza EB: Corticotrophin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders. Psychoneuroendocrinol (1995) 20:789-819.
15. De Souza EB, Battaglia G: CRH receptors in brain. Adv Exp Med Biol (1988) 245:123-136.
16. Coste SC, Kesterson RA, Helldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR, Hatton DC, Phillips TJ, Finn DA et al: Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotrophin-releasing hormone receptor-2. Nat Genet (2000) 24:403-409.
17. Holets VR: The anatomy and function of noradrenaline in the mammalian brain. In: The Pharmacology of Noradrenaline in the Central Nervous System. Heal DJ, Marsden CA (Eds), Oxford University Press, NY, USA (2000):1-27.
18. Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W: Interleukin 1 stimulates the secretion of hypothalamic-corticotropin-releasing factor. Science (1987) 238:522-524.
19. Lorens SA, Hata N, Handa RJ, Van De Kar LD, Guschwan M, Goral J, Lee JM, Hamilton ME, Bethea CL, Clancy J et al: Neurochemical, endocrine and immunologic responses to stress in young and old Fisher 344 rats. Neurobiol Aging (1990) 11:139-150.
20. Sapolsky RM, Krey LC, McEwen BS: The neuroendocrinology of stress and aging: The glucocorticoid cascade hypothesis. Endocr Rev (1986) 7:287-301.
21. Hauger RL, Thrivikraman KV, Plotsky PM: Age-related alterations of hypothalamic-pituitary-adrenal axis function in male Fischer 344 rats. Endocrinology (1994) 134:1528-1536.
22. Kasckow JW, Regmi A, Mulchahey JJ, Plotsky PM, Hauger RL: Changes in brain corticotropin-releasing factor messenger RNA expression in aged Fischer 344 rats. Brain Res (1999) 822:228-230.
23. Heroux JA, Grogoriadis DE, De Souza EB: Age-related decreases in corticotropin-releasing factor (CRF) receptors in rat brain and anterior pituitary gland. Brain Res (1991) 542:155-158.
24. Calza L, Giardino L, Velardo A, Battistini N, Marrama P: Influence of aging on the neurochemical organization of the rat paraventricular nucleus. J Chem Neuroanat (1990) 3:215-231.
25. Cizza G, Calogero LS, Brady G, Bagdy G, Bergamini E, Blackman MR, Chrousos GP, Gold PW: Male Fischer-344/N rats show a progressive impairment of the hypothalamic-pituitary-adrenal axis with advancing age. Endocrinology (1994) 134:1611-1620.
26. Deuschle M, Gotthardt U, Schweiger U, Weber B, Korner A, Schmider J, Standhardt H, Lammers CH, Heuser I: With aging in humans, the activity of the hypothalamus-pituitary-adrenal system increases and its diurnal attitude flattens. Life Sci (1997) 61:2239-2246.
27. Maes M, Calabrese J, Lee M, Meltzer HY: Effects of age on spontaneous cortisolaemia of normal volunteers and depressed patients. Psychoneuroendocrinol (1995) 19:79-84.
28. Born J, Ditschuneit I, Schreiber M, Dodt C, Fehm HL: Effects of age and gender on pituitary-adrenocortical responsiveness in humans. Eur J Endocrinol (1995) 132:705-711.
29. Heuser IJ, Gotthardt U, Schweigger J, Schmider J, Lammers CH, Dettling M, Holsboer F: Age-associated changes of pituitary-adrenocortical hormone regulation in humans: Importance of gender. Neurobiol Aging (1994) 15:227-231. During aging gthe glucocorticoid feedback system becomes insensitive; however, this study suggests that females secrete more hormone than males.
30. 1] CRF. Endocrinol (1986) 119:2129-2141.
31. Raadsheer FC, Sluiter AA, Ravid R, Tilders FJ, Swaab DF: Localization of corticotropin-releasing hormone (CRH) neurons in the paraventricular nucleus of the human hypothalamus; Age-dependent colocalization with vasopressin. Brain Res (1993) 615: 50-62.
32. Raber J: Detrimental effects of chronic hypothalamic-pituitary adrenal axis activation. Mol Neurobiol (1998) 18:1-22.
33. Bissette G, Nemeroff CB: The neurobiology of aging and Alzheimer's disease. Clin Neuropharmacol (1992) 15:33A-34A.
34. Sapolsky RM, Krey LC, McEwen BS: The neuroendocrinology of stress and aging: The glucocorticoid cascade hypothesis. Endocr Rev (1986) 7:284-304.
35. Sapolsky RM, Zola-Morgan S, Squire LR: Inhibition of glucocorticoid secretion by the hippocampal formation in the primate. J Neurosci (1991) 11:3695-3704.
36. McEwen B: Re-examination of the glucocorticoid hypothesis of stress and aging. Prog Brain Res (1992) 93:365-381.
37. Dodt C, Dittmann J, Hruby J, Spath-Schwalbe E, Born J, Schuttler R, Fehm HL: Different regulation of adrenocorticotropin and cortisol secretion in young, mentally healthy elderly and patients with senile dementia of Alzheimer's type. J Clin Endocrinol Metab (1991) 72:272-226.
38. Peiffer A, Barden N, Meaney MJ: Age-related changes in glucocorticoid receptor binding and mRNA levels in the rat brain and pituitary. Neurobiol Aging (1991) 12:475-479.
39. Issa AM, Rowe W, Gauthier S, Meant MJ: Hypothalamic-pituitary-adrenal activity in aged, cognitively impaired and cognitively unimpaired rats. J Neurosci (1990) 10:3247-3254.
40. Kerr DS, Campbell LW, Applegate MD, Brodish A, Landfield PW: Chronic stress-induced acceleration of electrophysiologic and morphometric biomarkers of hippocampal aging. J Neurosci (1991) 11:1316-1324.
41. Pedersen WA, McCullers D, Culmsee C, Haughey NJ, Herman JP, Mattson MP: Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease. Neurobiol Dis (2001) 8:492-503.
42. Davidson M, Bastiaens L, Davis BM, Shah MB, Davis KL: Endocrine changes in Alzheimer's disease. Endocrinol Metab Clin NA (1988) 17:149-155.
43. Nasman B, Olsson T, Fagerlund T, Viitanen M, Carlstrom K: A subtle disturbance in the feedback regulation of the hypothalamic-pituitary-adrenal axis in the early phase of Alzheimer's disease. Psychoneuroendocrinol (1995) 20: 211-220.
44. Nasman B, Olsson T, Fagerlund M, Eriksson S, Viitanen M, Carlstrom K: Blunted adrenocorticotropin and increased adrenal steroid response to human corticotropin-releasing hormone in Alzheimer's disease. Biol Psychiatry (1996) 39:311-318.
45. Odio M, Brodish A: Age-related adaption of pituitary-adrenocortical responses to stress. Neuroendocrinol (1989) 49:382-388. Adrenocortical response to stress was similar in young and old rats on the first exposure, to stress; by the third exposure, corticosterone responses were lower in older rats.
46. Lupien S, Lecours AR, Lussier I, Schwartz G, Nair NPY, Meaney MJ: Basal cortisol levels and cognitive deficits in human aging. J Neurosci (1994) 14:2893-2903.
47. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A: Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. J Clin Psychiatry (1987) 48:9-15.
48. Deshmukh VD, Deshmukh SV: Stress-adaptation failure hypothesis of Alzheimer's disease. Med Hypotheses (1990) 32:293-295.
49. Bissette G, Reynolds GP, Kilts CD, Widerlov E, Nemeroff CB: Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. J Am Med Assoc (1985) 254:3067-3069.
50. Whitehouse PJ, Vale WW, Zweig RM, Singer HS, Mayeux R, Kuhar MJ, Price DL, De Souza EB: Reduction in corticotropin-releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy. Neurology (1987) 37:905-909.
51. De Souza EB, Bissett G, Whitehouse PJ, Price DL, Vale WW, Nemeroff CG: Role of corticotropin-releasing factor (CRF) in neurodegenerative diseases. In: Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide. De Souza EB, Nemeroff CB (Eds), CRC Press, FL, USA (1990).
52. Powers RE, Walker LC, De Souza EB, Vale WW, Struble RG, Whitehouse PJ, Price DL: Immunohistochemical study of neurons containing CRF in Alzheimer's disease. Synapse (1987) 1:405-410.
53. Raadsheer FC, Van Heerikhuize JJ, Lucassen PJ, Hoogendijk WJ, Tilders FJ, Swaab DF: Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression. Am J Psych (1995) 152:1372-1376.
54. Pomara N, Singh RR, Deptula D, LeWitt PA, Bissette G, Stanley M, Nemeroff CB: CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: Its relationship to severity of dementia and monoamine metabolites. Biol Psychiatry (1989) 26:500-504.
55. Mouradian MM, Farah JM, Mohr E, Fabbrini G, O'Donohue TL, Chase TN: Spinal fluid CRF reduction in Alzheimer's disease. Neuropeptides (1986) 8:393-400.
56. Dodt C, Dittman J, Hruby J, Spath-Schwalbe E, Born J, Schuttler R, Fehm HL: Different regulation of adrenocorticotropin and cortisol secretion in young, mentally healthy elderly and patients with senile dementia of Alzheimer's type. J Clin Endocrinol Metab (1991) 72:272-276.
57. De Souza EB, Battaglia G: Increased corticotropin-releasing factor receptors in rat cerebral cortex following chronic atropine treatment. Brain Res (1986) 397:401-404.
58. 2+ homeostasis and cell death. J Neurosci (1995) 15:6239-6249.
59. Pedersen WA, McCullers D, Culmsee C, Haughey NJ, Herman JP, Mattson MP: Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease. Neurobiol Dis (2001) 8:492-503. CRH was protective against Aβ-induced toxicity in a primary neuronal culture. This effect was blocked by a CRH receptor antagonist.
60. Davies P, Katzman R, Terry RD: Reduced somatostatin immunoreactivity in cerebral cortex from cases of Alzheimer senile dementia. Nature (1980) 288:279-280.
61. Ferrara C, Cocchi D, Müller EE: Somatostatin in the hippocampus mediates dexamethasone-induced suppression of corticosterone secretion in rat. Neuroendocrinol (1991) 53:428-431.
62. Cacabelos R, Niigawa H, Ikemura Y, Yanagi Y, Tanaka S, Rodriguez-Amao MD, Gomez-Pan A, Nishimura T: GHRH-induced GH response in patients with senile dementia of the Alzheimer's type. Acta Endocrinol (1988) 117:295-301.
63. Heuser I, Baronti F, Marin CA, Ma N, Merriam GR, Chase TN, Mouradian MM: Growth hormone secretion in Alzheimer's disease: 24-Hour profile of basal levels and response to stimulation and suppression studies. Neurobiol Aging (1992) 13:255-260.
64. Sonntag W, Gottschall P, Meites J: Increased secretion of somatostatin-28 from hypothalamic neurons of aged rats in vitro. Brain Res (1986) 380:229-234.
65. Lima K, Dall' Ara A, Parenti M, Rusconi L, Muller EE, Cocchi D: Replenishment of brain catecholamine stores does not restore the impaired growth hormone (GH) responsiveness to GHRH in aged rats. Pharmacol Res (1989) 21:87-88.
66. Mouradian MM, Blin J, Giuffra M, Heuser IJ, Baronti F, Ownby J, Chase TN: Somatostatin replacement therapy for Alzheimer dementia. Ann Neurol (1991) 30:610-613.
67. Schultz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P, Tingley FD 3rd, Winston EN, Chen YL, Heym J: CP-154,526: A potent and selective nonpeptide anatagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA (1996) 93:10477-10482.
68. Behan DP, Heinrichs SC, Troncoso JC, Liu XJ, Kawas CH, Ling N, De Souza EB: Displacement of corticotropin releasing factor from its binding protein as a possible treatment for Alzheimer's disease. Nature (1995) 378:284-287.
69. Whitehouse PJ, Vale WW, Zweig RM, Singer HS, Mayeux R, Kuhar MJ, Price DL, De Souza EB: Reduction in corticotropin-releasing factor-like immunoreactivity in cerebral cortex in Alzheimer's disease, Parkinson's disease, and progressive supranuclear palsy. Neurology (1987) 37:905-909.
70. Conte-Devolx B, Grino M, Neioullon A, Javoy-Agid F, Castanas E, Guillaume V, Tonon MC, Vaudry H, Oliver C: Corticoliberin, somatocrinin and amine contents in normal and parkinsonian human hypothalamus. Neurosci Lett (1985) 56:217-222. Levels of corticoliberin and somatocrinin were no different in PD hypothalami than in controls. However, levels of DA were reduced by 50% in these brains compared to controls.
71. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbarin A, Tomlinson BE, Perry RH: Cholinergic correlates of cognitive impairment in Parkinson's disease: Comparisons with Alzheimer's disease. J Neurol Neurosurg Psych (1985) 48:413-421.
72. Epelbaum J, Ruberg M, Moyse E, Javoy-Agid F, Dubois B, Agid Y: Somatostatin and dementia in Parkinson's disease. Brain Res (1983) 278:376-379.
73. Kish SJ, Chang LJ, Mirchandani L, Shannak K, Hornykiewicz O: Progressive supranuclear palsy: Relationship between extrapyramidal disturbance, dementia and brain neurotransmitter markers. Ann Neurol (1985) 18:530-536. Four of five patients who had died with PSP had a marked nigrostriatal DA deficiency although DA levels were normal in the nucleus accumbens, hypothalamus and temporal cortex. Levels of other neurotransmitters appeared to be normal.
74. De Souza EB, Whitehouse PJ, Folstein SE, Price DL, Vale WW: Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease. Brain Res (1987) 437:355-359. The concentration of CRH-IH was decreased in the caudate/putamen of patients with HD put appeared normal in other areas examined. This group also had increased somatostatin-like immunoreactivity in the caudate/putamen.